Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation (NasdaqGM: ADLR) today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

“We look forward to reporting results from these studies in the summer of 2011 and moving the program forward into pivotal studies in early 2012.”

The Company's first Phase 2 study of this compound initiated in October 2010 and is evaluating two doses of ADL5945 (0.10 mg and 0.25 mg) each administered twice daily in patients with OIC. This second Phase 2 study of ADL5945, which will assess a single dose of 0.25 mg once daily versus placebo in the same study design, is intended to complete the dosing assessment of ADL5945 in anticipation of a Phase 3 program.

"The addition of this once-daily dosing study will expand our understanding of the efficacy, safety and tolerability of ADL5945, and the successful completion of the Phase 2 program should enable us to select a dose for pivotal confirmatory studies," said Michael R. Dougherty, President and Chief Executive Officer. "We look forward to reporting results from these studies in the summer of 2011 and moving the program forward into pivotal studies in early 2012."